SABCS 2010: Combination of Tivozanib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptors (VEGFRs), With Weekly Paclitaxel for Metastatic Breast Cancer: Preliminary Results of an Ongoing Phase 1 Study
TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)
